Accelerox
Jump to navigation
Jump to search
ACELEROX is developing novel antioxidant nanoparticles that serve as therapies for reactive oxygen species (ROS)-mediated disease. ROS has been implicated in the progression of a broad range of diseases, including rheumatoid arthritis, multiple sclerosis, ischemic stroke and traumatic brain injury. The companys proprietary class of molecules, termed PEG-HCCs, can be used to directly treat the symptoms of these diseases as well as to deliver chemotherapeutic drugs into tumors.
| Accelerox | |
|---|---|
| Startup Information | |
| Website | http://fannininnovation.com/portfolio/acelerox/ |
| Industry | |
| Accelerator | Fannin Innovation Studio |
| Accelerator (Other) | |
| Founder | |
| Founding Date | |
| Street Address | |
| City | |
| Zip Code | |
| Copyright © 2016 McNair Center. All Rights Reserved. | |
